Abstract
The objective of this study was to determine whether neonatal-perinatal fellowship programs (NFTPs) in the United States vary in indomethacin use for the management of patent ductus arteriosus (PDA) in ≤28 week gestational age infants at birth. A 53-item web-based survey was sent to 84 NFTP directors who received prenotification, followed 2 weeks later by a reminder letter. A total of 56 NFTP directors responded (67% maximum response rate). Wide variation exists in the maximum number of indomethacin courses used to close ductus, use of indomethacin for reopened PDA beyond 14 days, ductal closure definition, contraindications before consideration of indomethacin, interventions for contraindications, and reported ductal closer rate after each indomethacin course. Indomethacin therapy for symptomatic PDA and short course of indomethacin are common practices. Indomethacin use for the management of PDA in premature infants varies among NFTP directors. Practice attitudes may explain variations in ductal closure and ligation rates. Because practice variations may have implications for long-term outcome of vulnerable premature infants, studies relevant to the management of PDA in premature infants are needed.
Similar content being viewed by others
References
American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. Available at http://www.aapor.org/pdfs/standarddefs_4.pdf.
Amin SB, Glantz CJ (2006) Effect of antenatal indomethacin on neonatal outcomes: meta-analysis of observational studies. EPAS 59:4858.290 [abstract]
Asch DA, Jedrziewski MK, Christakis NA (1997) Response rates to mail surveys published in medical journals. J Clin Epidemiol 50:1129–1136
Asthana S, Amin SB (2006) Neonatal outcomes after multiple courses of postnatal indomethacin for patent ductus arteriosus. EPAS 59:2863.249 [abstract]
Barrington K, Brion LP (2002) Dopamine verses no treatment to prevent renal dysfunction in indomethacin treated preterm newborn infants. Cochrane Database Syst Rev 3:CD003213
Baumeister L, Marchi K, Pearl M, Williams R, Braveman P (2000) The validity of information on “race” and “Hispanic ethnicity” in California birth certificate data. Health Serv Res 35:869–883
Braithwaite D, Emery J, DeLusignan S, Sutton S (2003) Using the Internet to conduct surveys of health professionals: a valid alternative? Fam Pract 20:545–551
Brion LP, Campbell DE (2001) Furosemide for symptomatic patent ductus arteriosus in indomethacin treated infants. Cochrane Database Syst Rev 3:CD001148
Clyman RI (1996) Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 128:601–607
Cotton RB, Stahlman MT, Kovar I, Catterton WZ (1978) Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 92:467–473
Cull W, O’Connor KG, Sharp S, Tang SS (2005) Response rates and response bias for 50 surveys of pediatricians. Health Serv Res 40:213–226
Dollberg S, Lusky A (2005) Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population based study. J Pediatr Gastroenterol Nutr 40:184–188
Fowlie PW, Davis PG (2003) Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 88:F464–F466
Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS (1983) Effects of indomethacin on premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 102:895–906
Golombek SG, LaGamma EF, Paneth N (2002) Treatment of transient hypothyroxinemia of prematurity: a survey of neonatal practice. J Perinatol 22:563–565
Gomez SL, Kelsey JL, Glaser SL, Lee MM, Sidney S (2005) Inconsistencies between self-reported ethnicity and ethnicity recorded in a health maintenance organization. Ann Epidemiol 15:71–79
Gonzalez A, Sosenko IR, Chander J, et al. (1996) Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 gram or less. J Pediatr 128:470–478
Grol R (2000) Implementation of evidence and guidelines in clinical practice: a new field of research? Int J Qual Health Care 12:455–456
Hammerman C (1995) Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 22:457–479
Hammerman C, Aramburo MJ (1990) Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr 117:771–776
Herrera C, Holberton J, Davis P (2004) Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 1:CD003480
Itabashi K, Ohno T, Nishida H (2003) Indomethacin responsiveness of patent ductus arteriosus and subsequent renal abnormalities in preterm infants treated with indomethacin. J Pediatr 143:203–207
Keller RL, Clyman RI (2003) Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 112:583–587
Kluckow M, Evans N (2000) Ductal shunting, high pulmonary blood flow and pulmonary hemorrhage. J Pediatr 137:68–72
Kresch MJ, Moya FR, Ascuito RJ, Ross-Ascuito NT, Heusser F (1988) Late closure of the ductus arteriosus using indomethacin in the preterm infant. Clin Pediatr 27:140–143
Lee J, Rajadurai VS, Tan KW, et al. (2003) Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics 112:345–350
Leviton LC, Orleans CT (2003) Promoting the uptake of evidence in clinical practice: a prescription for action. Clin Perinatol 30:403–417
Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI (1982) Prophylactic indomethacin therapy for patent ductus arteriosus in very low birth weight infants. N Engl J Med 6:506–510
McCarthy JS, Zies LG, Gelband H (1978) Age dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics 62:706–712
Narayanan M, Cooper B, Weiss H, Clyman RI (2000) Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 136:330–337
Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI (1993) Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 329:1602–1607
Rennie JM, Cooke RW (1991) Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child 66:55–58
Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J (1988) Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr 147:481–484
Rojas M, Gonzalez A, Bancalari E, et al. (1995) Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126:605–610
Schmidt B, Davis P, Moddemann D, et al. (2001) Long term effects of indomethacin prophylaxis in extremely low birth weight infants. N Engl J Med 344:1966–1972
Sheehan K (2001) E-mail survey response rates: a review. J Comput Mediated Commun 6. Available at http://www.informatik.uni-trier.de/uley/to/Journals/jcmc/jcmcG.html
Tammela O, Ojala R, Iivainen T, et al. (1999) Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 134:552–557
Acknowledgments
This work was supported by grant DC 006229-01 from National Institute on Deafness and Other Communication Disorders. We thank the neonatal fellowship program directors who participated in the survey and those who pretested the questionnaire.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amin, S.B., Handley, C. & Carter-Pokras, O. Indomethacin Use for the Management of Patent Ductus Arteriosus in Preterms: A Web-Based Survey of Practice Attitudes Among Neonatal Fellowship Program Directors in the United States. Pediatr Cardiol 28, 193–200 (2007). https://doi.org/10.1007/s00246-006-0093-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-006-0093-1